Cytokinetics, Incorporated
Cytokinetics, Incorporated
Join ActionIf you are a Cytokinetics investor who suffered a loss and would like to learn more, you can provide your information below:
If you suffered losses in Cytokinetics between December 27, 2023 and May 6, 2025, both dates inclusive (the “Class Period”) Securities Litigation Partner James (Josh) Wilson encourages you to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) or you can submit your information below.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) and reminds investors of the November 17, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
CASE DETAILS: According to the complaint, defendants made materially false and misleading statements regarding the timeline for the New Drug Application (“NDA”) submission and approval process for aficamten. Specifically, defendants represented that the Company expected approval from the U.S. Food and Drug Administration (“FDA”) for its NDA for aficamten in the second half of 2025, based on a September 26, 2025 PDUFA date, and failed to disclose material risks related to the Company’s failure to submit a Risk Evaluation and Mitigation Strategy (“REMS”) that could delay the regulatory process.
STOCK DROP: On May 6, 2025, during an earnings call, it was revealed that the Company had multiple pre-NDA meetings with the FDA discussing safety monitoring and risk mitigation but chose to submit the NDA without a REMS, relying on labeling and voluntary education materials. This confirmed defendants’ awareness of potential REMS requirements and their reckless decision to omit it from the initial submission, misleading investors about the regulatory timeline.
As a result of defendants’ false and misleading statements, class members purchased Cytokinetics’ common stock at artificially inflated prices and suffered significant losses when the truth was revealed.
WHAT’S NEXT? If you incurred a loss in Cytokinetics during the class period, you have until the November 17, 2025 deadline, to petition the Court for appointment as lead plaintiff. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Cytokinetics’ conduct to contact the firm, including whistleblowers, former employees, shareholders and others. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
